See Article, page XXX
To read this article in full you will need to make a payment
Primary sclerosing cholangitis – a comprehensive review.
J Hepatol. 2017; 67: 1298-1323
New therapeutic concepts in bile acid transport and signaling for management of cholestasis.
Hepatology. 2017; 65: 1393-1404
New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond.
J Hepatol. 2015; 62: S25-S37
Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease.
Gut. 2011; 60: 463-472
Therapy of primary sclerosing cholangitis–today and tomorrow.
Dig Dis. 2015; 33: 149-163
A placebo-controlled trial of obeticholic acid in primary biliary cholangitis.
N Engl J Med. 2016; 375: 631-643
Progress and challenges of selective Farnesoid X Receptor modulation.
Pharmacol Ther. 2018; 191: 162-177
Nonsteroidal FXR ligands: current status and clinical applications.
Handb Exp Pharmacol. 2019; 256: 167-205
Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23.
Nat Rev Drug Discov. 2016; 15: 51-69
The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis.
Hepatology. 2019; 70: 788-801
Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial.
J Hepatol. 2019; 70 (30414864): 483-493
A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
J Hepatol. 2020; ([Epub ahead of print])
norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.
J Hepatol. 2017; 67: 549-558
Ursodiol for primary sclerosing cholangitis. Mayo primary sclerosing cholangitis-ursodeoxycholic acid study group.
N Engl J Med. 1997; 336: 691-695
Surrogate endpoints for clinical trials in primary sclerosing cholangitis: review and results from an International PSC Study Group consensus process.
Hepatology. 2016; 63: 1357-1367
Prolonged fibroblast growth factor 19 response in patients with primary sclerosingcholangitis after an oral chenodeoxycholic acid challenge.
Hepatol Int. 2017; 11: 132-140
Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression.
Biochim Biophys Acta Mol Basis Dis. 2018; 1864: 1335-1344
Cilofexor, a nonsteroidal FXR agonist, in non-cirrhotic patients with nonalcoholic steatohepatitis: a phase 2 randomized controlled trial.
Hepatology. 2020; ([Epub ahead of print])
Pruritus in cholestasis: facts and fiction.
Hepatology. 2014; 60: 399-407
FXR-dependent modulation of the human small intestinal microbiome by the bile acid derivative obeticholic acid.
Gastroenterology. 2018; 155: 1741-1752
Published online: May 29, 2020
In Press Journal Pre-Proof
© 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Access this article on ScienceDirect